Open AccessIgE‐mediated histamine release from nasal mucosa is inhibited by SLPI (secretory leukocyte protease inhibitor) to the level of spontaneous release
Author(s) -
Ulla Westin,
E. Lundberg,
K. Ohlsson
Publication year - 1998
Publication title -
mediators of inflammation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.37
H-Index - 97
eISSN - 1466-1861
pISSN - 0962-9351
DOI - 10.1080/09629359891162
Subject(s) - slpi , histamine , protease inhibitor (pharmacology) , cathepsin g , immunoglobulin e , proteases , immunology , neutrophil elastase , elastase , in vitro , pharmacology , chemistry , biology , enzyme , biochemistry , inflammation , antibody , antiretroviral therapy , viral load , human immunodeficiency virus (hiv)
The secretory leukocyte protease inhibitor (SLPI) is a low-molecular-weight inhibitor of proteases, such as elastase and cathepsin G which are released from leukocytes during phagocytosis. The purpose of this study was to determine whether or not SLPI is able to inhibit IgE-mediated histamine release. Nasal mucosa from 11 test subjects without atopic disposition was used for this in vitro study. We found that SLPI inhibited histamine release in a dose-dependent way but was without influence on the spontaneous release.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom